OlympiA
Adjuvant Olaparib for High-Risk gBRCA-Mutant Early Breast Cancer
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 1,836 patients with HER2-negative, high-risk early breast cancer and germline BRCA1/2 mutation, one year of adjuvant olaparib reduced invasive disease-free survival events compared with placebo.
N
1.836
Design
Double-blind RCT
Endpunkt
Invasive disease-free survival
Relevanz
2
Ergebnis3-yr iDFS 85.9% vs 77.1% (HR 0.58). 4-yr OS 89.8% vs 86.4% (HR 0.68).
Tutt ANJ, et al. N Engl J Med. 2021;384(25):2394-2405. 10.1056/NEJMoa2105215
Diskussion & Kritik
First positive PARP-inhibitor trial in (neo)adjuvant breast cancer. Requires upfront germline BRCA testing, including in early-stage disease.